Project Grant R21CA296660
Award Date 9/9/25
Completion Date 8/31/27
Dollars Obligated $183K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Arizona, USA
Similar Awards
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $313,963 to Z Biotech, LLC to develop a comprehensive library and array of tumor-associated carbohydrate antigens (TACA). The goal is to create tools to systematically evaluate TACA interactions with therapeutic antibodies, biologics, and glycan-binding proteins, in order to advance the development of TACA-targeted...
- This federal Project Grant award of $418,176 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development and validation of a novel approach called "Programmable Nucleic Acid Cytometry" at the Sloan-Kettering Institute for Cancer Research. The project aims to advance this innovative method for profiling rare cell populations from tumors and tissues, which offers advantages over traditional antibody-based cell isolation techniques. The work will...
- This federal Project Grant award of $185,760 from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) aims to support research to investigate the role of glycerol metabolism in anti-tumor immunity. The research, conducted by the University of Chicago, will determine the immunomodulatory effects of glycerol on CD8+ T cells and examine the metabolic interactions between cancer cells and T cells. The project will also explore methods to improve anti-tumor immunity by...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Glytr Therapeutics, Inc. to maximize the effectiveness of their pan-cancer immunotherapy platform based on Glycan-dependent T cell Recruiter (GLYTR) technologies. The $463,510 award, granted on September 10, 2025, supports research to enhance the target density and broaden the applicability of GLYTR1 bi-specific antibodies and GLYTR2 chimeric antigen receptor (CAR)...
- The Project Grant award of $424,734 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of a novel spatial proteomics approach to profile immune cell types and their locations within a tumor microenvironment. The University of Illinois, the awardee, aims to integrate 3D microscopy techniques with bottom-up proteomic assays to offer deep proteome profiles of specific immune cells at various subregions of a mouse tumor (Aims 1 and 2). The goal is...
- This federal Project Grant award of $672,371.00 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research at Yale University to develop ultra-sensitive mass spectrometry-based immunopeptidomics using digital microfluidics. The project aims to improve the identification of tumor-specific antigens (TSAs) to support the development of effective cancer immunotherapies. The award has a performance period from September 1, 2025...
- This federal Project Grant award of $419,133, provided by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of the AscitesPredict technology. AscitesPredict is a novel "ex vivo tumor biosensor" that leverages single-cell technologies to evaluate cell identities and therapeutic sensitivities in patient ascites samples, which are often discarded despite being a plentiful and representative tumor source. The...
- This $3,130,492 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to improve understanding of the fundamental biological mechanisms driving the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EA), a highly lethal cancer. The project, conducted by Arizona State University, aims to develop computational methods to analyze the spatial structure and cell type diversity in BE tissue biopsies in...
- The National Cancer Institute (NCI) awarded a $919,366 Project Grant to Nuvox Pharma, L.L.C., a small disadvantaged business located in Tucson, Arizona, under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394). The goal of this 2-year project, running from September 2025 to August 2027, is to evaluate liquid biopsy approaches to differentiate pseudoprogression from true disease progression in glioblastoma (GBM) patients treated with chemoradiation and an oxygen...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding of $364,367 to Montana Molecular LLC to develop fluorescent biosensors for measuring the signaling kinetics of G-protein coupled receptor (GPCR) ligands that activate the G12/13 signaling pathways. The goal is to create a live-cell, fluorescent assay that can be used on standard plate readers to provide kinetic data on G12/13 pathway activation in response to different...